Co-Diagnostics' India Joint Venture Launches Clinical Studies for Tuberculosis Test

MT Newswires Live07-22 21:27

Co-Diagnostics (CODX) said Wednesday that its CoSara Diagnostics joint venture in India is initiating clinical studies for its tuberculosis test on the CoSara PCR Pro instrument.

The company said the CoSara PCR Pro instrument, which is the CoSara-branded version of the Co-Dx PCR Pro point-of-care instrument, is being deployed in select labs across India for tuberculosis testing evaluation.

Co-Dx PCR platform products, including PCR test kits and the sample lysis instrument, are expected to be manufactured and distributed in India under the CoSara brand, the company said.

The Co-Dx PCR platform and associated tests remain subject to review or authorization by applicable regulatory authorities and are not yet available for sale.

Shares of Co-Diagnostics were up more than 8% pre-bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653471763?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653471763","market":"hk","top_or_hot":-1,"title":"Co-Diagnostics' India Joint Venture Launches Clinical Studies for Tuberculosis Test","media":"MT Newswires Live","content":"<html><body><p> Co-Diagnostics (CODX) said Wednesday that its CoSara Diagnostics joint venture in India is initiating clinical studies for its tuberculosis test on the CoSara PCR Pro instrument.</p><p>The company said the CoSara PCR Pro instrument, which is the CoSara-branded version of the Co-Dx PCR Pro point-of-care instrument, is being deployed in select labs across India for tuberculosis testing evaluation.</p><p>Co-Dx PCR platform products, including PCR test kits and the sample lysis instrument, are expected to be manufactured and distributed in India under the CoSara brand, the company said.</p><p>The Co-Dx PCR platform and associated tests remain subject to review or authorization by applicable regulatory authorities and are not yet available for sale.</p><p>Shares of Co-Diagnostics were up more than 8% pre-bell.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Co-Diagnostics' India Joint Venture Launches Clinical Studies for Tuberculosis Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCo-Diagnostics' India Joint Venture Launches Clinical Studies for Tuberculosis Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-22 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Co-Diagnostics (CODX) said Wednesday that its CoSara Diagnostics joint venture in India is initiating clinical studies for its tuberculosis test on the CoSara PCR Pro instrument.</p><p>The company said the CoSara PCR Pro instrument, which is the CoSara-branded version of the Co-Dx PCR Pro point-of-care instrument, is being deployed in select labs across India for tuberculosis testing evaluation.</p><p>Co-Dx PCR platform products, including PCR test kits and the sample lysis instrument, are expected to be manufactured and distributed in India under the CoSara brand, the company said.</p><p>The Co-Dx PCR platform and associated tests remain subject to review or authorization by applicable regulatory authorities and are not yet available for sale.</p><p>Shares of Co-Diagnostics were up more than 8% pre-bell.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CODX","symbol_name":"Co-Diagnostics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653471763","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653471763","pubTimestamp":1784726864,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Co-Diagnostics  said Wednesday that its CoSara Diagnostics joint venture in India is initiating clinical studies for its tuberculosis test on the CoSara PCR Pro instrument.The company said the CoSara PCR Pro instrument, which is the CoSara-branded version of the Co-Dx PCR Pro point-of-care instrument, is being deployed in select labs across India for tuberculosis testing evaluation.Co-Dx PCR platform products, including PCR test kits and the sample lysis instrument, are expected to be manufactured and distributed in India under the CoSara brand, the company said.The Co-Dx PCR platform and associated tests remain subject to review or authorization by applicable regulatory authorities and are not yet available for sale.Shares of Co-Diagnostics were up more than 8% pre-bell.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CODX":"Co-Diagnostics, Inc.","BK4185":"保健护理机构","BK4568":"美国抗疫概念","JYNT":"The Joint Corp.","BK4082":"医疗保健设备"},"translate_title":"Co-Diagnostics 印度合资企业启动结核病检测临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JYNT":1.5,"CODX":1,"MNDmain":1.5},"content_text":"Co-Diagnostics (CODX) said Wednesday that its CoSara Diagnostics joint venture in India is initiating clinical studies for its tuberculosis test on the CoSara PCR Pro instrument.The company said the CoSara PCR Pro instrument, which is the CoSara-branded version of the Co-Dx PCR Pro point-of-care instrument, is being deployed in select labs across India for tuberculosis testing evaluation.Co-Dx PCR platform products, including PCR test kits and the sample lysis instrument, are expected to be manufactured and distributed in India under the CoSara brand, the company said.The Co-Dx PCR platform and associated tests remain subject to review or authorization by applicable regulatory authorities and are not yet available for sale.Shares of Co-Diagnostics were up more than 8% pre-bell.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653471763","isCrawlerRequest":true}